Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin with FBR Conditioning for Allo-SCT in Lymphoid Malignancies
NCT01664910Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2012
- Primary completion
- Jun 2023
- Countries
- 1
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Conditions
- lymphoid malignancy
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in lymphoid malignancy, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum-tolerated Dose of Inotuzumab Without DLT at 30 days. Started Oct 2012; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment (transplant)
Inotuzumab ozogamicin + FBR conditioning followed by Allo-SCT
03
Endpoints
Primary
Maximum-tolerated Dose of Inotuzumab Without DLT
Secondary
Overall Response
Overall Survival
Event-Free Survival
Beyond the preview
Go deeper on NCT01664910.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01664910.